Suppr超能文献

美国人群中存在中度至重度高同型半胱氨酸血症的估计患病率:这是漏诊高胱氨酸尿症的机会吗?

Estimated prevalence of moderate to severely elevated total homocysteine levels in the United States: A missed opportunity for diagnosis of homocystinuria?

机构信息

Orphan Technologies, 430 Bedford St, Lexington, MA 02420, USA.

LapidusData Inc., 321 NE 4th St, Oklahoma City, OK 73104, USA.

出版信息

Mol Genet Metab. 2020 May;130(1):36-40. doi: 10.1016/j.ymgme.2020.02.001. Epub 2020 Feb 5.

Abstract

Classical homocystinuria (HCU) is a genetic disorder caused by mutations in the cystathionine beta synthase gene, which results in impaired metabolism of the sulfur-bearing amino acid homocysteine and its accumulation in blood and tissues. Classical HCU can be detected via newborn screening in the United States, but the test is widely acknowledged to miss many patients. While severely elevated homocysteine levels (>100 μmol /L) frequently lead to a classical HCU diagnosis, intermediate levels (>30 to 100 μmol /L), though linked to many of the known complications of HCU, are not always recognized as associated with HCU. We aimed to identify and describe potentially undiagnosed classical HCU patients using a nationally-representative database of administrative claims and laboratory results. We estimated the national prevalence of patients with homocysteine >30 μmol /L, and compared their demographic and clinical characteristics to those of patients with homocysteine levels ≤30 μmol/L. Among 57,580 patients with a homocysteine test result, 1.8% had a value >30 μmol /L. Patients with homocysteine >30 μmol /L were more frequently diagnosed with hypothyroidism (39.2% vs. 20.7%, p < .001) and renal disease (9.7% vs. 5.5%, p < .001), and were more likely to have a prescription for an anxiolytic/antidepressant (44.5% vs. 38.9%), opioid (58.4% vs. 53.1%), steroid (46.4% vs. 42.5%), or thyroid hormone (38.8% vs. 18.8%), compared to patients with homocysteine ≤30 μmol /L (all p < .05). Both groups were equally likely to have a diagnosis of homocystinuria or another disorder of sulfur-bearing amino acid metabolism (3.8% vs. 4.0%, p = .752). The age-adjusted national prevalence of homocysteine >30 μmol /L was estimated at 33,068 (95% CI: 1033 - 35,104). These findings suggest that thousands of people in the US may be living with intermediate to severely elevated homocysteine levels and may require further evaluation for the presence of classical HCU.

摘要

经典同型胱氨酸尿症(HCU)是一种由胱硫醚β合酶基因突变引起的遗传性疾病,导致含硫氨基酸同型半胱氨酸的代谢受损,其在血液和组织中蓄积。在美国,经典 HCU 可通过新生儿筛查检测到,但该检测被广泛认为会漏诊许多患者。虽然严重升高的同型半胱氨酸水平(> 100 μmol/L)常导致经典 HCU 诊断,但中间水平(> 30 至 100 μmol/L),尽管与 HCU 的许多已知并发症有关,但并不总是被认为与 HCU 有关。我们旨在使用全国代表性的行政索赔和实验室结果数据库来识别和描述可能未被诊断的经典 HCU 患者。我们估计了同型半胱氨酸> 30 μmol/L 的患者的全国患病率,并将其人口统计学和临床特征与同型半胱氨酸水平≤30 μmol/L 的患者进行了比较。在 57580 名接受同型半胱氨酸检测的患者中,有 1.8%的患者值> 30 μmol/L。同型半胱氨酸> 30 μmol/L 的患者更频繁地被诊断为甲状腺功能减退症(39.2% vs. 20.7%,p <.001)和肾脏疾病(9.7% vs. 5.5%,p <.001),并且更有可能开处方使用抗焦虑/抗抑郁药(44.5% vs. 38.9%)、阿片类药物(58.4% vs. 53.1%)、类固醇(46.4% vs. 42.5%)或甲状腺激素(38.8% vs. 18.8%),与同型半胱氨酸≤30 μmol/L 的患者相比(均 p <.05)。两组发生同型胱氨酸尿症或其他含硫氨基酸代谢紊乱的诊断率相当(3.8% vs. 4.0%,p =.752)。同型半胱氨酸> 30 μmol/L 的全国年龄调整患病率估计为 33068(95%CI:1033-35104)。这些发现表明,美国有数千人可能处于中间至严重升高的同型半胱氨酸水平,可能需要进一步评估是否存在经典 HCU。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验